Director Morgan Adam bought 1.77M HRTX shares at $1.50 (Aug 2025), growing stake 25.3%; stock now -48.6% from 52-week high, unprofitable company.
Morgan Adam, a director of Heron Therapeutics, purchased 1,766,546 shares at $1.50 on 2025-08-08, increasing his holdings from 6.99M to 8.75M shares—a 25.3% increase in position size for $2.6M. The stock has declined significantly since the transaction, now trading at $1.31 (-48.6% from its 52-week high of $2.55) and down 39.9% over the prior 30 days, raising questions about execution timing. The company remains unprofitable with a net loss of $2.4M in the latest quarter despite positive annual revenue growth of 13.6%, and Adam's prior trade at this ticker (a July 2023 buy) produced a -53.5% return over 90 days—a poor outcome that provides limited precedent for timing success in HRTX. This purchase signals substantial capital commitment by a director to a distressed biotech position, yet the post-transaction price action and company's ongoing losses underscore material execution and fundamental risks investors should monitor closely.